The U.S. Food and Drug Administration has accepted, for review, the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.
En una investigación reciente, se ha analizado la resistencia al deslizamiento de diferentes pavimentos utilizados en carriles para bicicletas El estudio lo ha realizado el equipo de David Llopis Castelló, de la Universidad Politécnica de Valencia (UPV) en España …
Transcarent will get 98point6’s self-insured employer business, affiliated physician group and a software license. Meanwhile, 98point6 will rebrand as 98point6 Technologies and focus on licensing its software to third-party providers.
Transcarent to acquire majority of telehealth platform 98point6 for $100M Read More »
El feocromocitoma es un tumor raro, con una incidencia de tres a ocho casos por millón de habitantes cada año. El mayor estudio genómico realizado hasta ahora del feocromocitoma identifica a los pacientes con más riesgo de metástasis y a los que responder& …
Hallazgos sobre el feocromocitoma, un cáncer raro Read More »
The regulatory decision gives the devices the green light to be used in artificial pancreas systems, and positions Abbott as a competitor to Dexcom in the space.
Abbott CGMs cleared to integrate with automated insulin delivery systems Read More »
While the extra time to comply is aimed at preventing medical device shortages, the rules have still left some device makers and certifying bodies unclear about how to proceed, says one attorney.
Medtech industry relieved as Europe’s MDR extension nears final approval Read More »
Una investigación reciente ha analizado los servicios de interacciones falsas en las redes sociales. Además de catalogar el ecosistema fraudulento de “likes”, reproducciones, seguidores o visitas online, el estudio señala los modelos económicos que lo sustenta …
Los servicios de interacciones falsas en las redes sociales, al descubierto Read More »
Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.
Voyager Rolls on as Novartis Selects Two of Three CNS Targets Read More »
The transcatheter repair clip beat the established medical therapy on the primary composite endpoint, setting up a battle with a rival company for a $5 billion market.
